Resorcinol-sn-glycerol derivatives: Novel 2-Arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor

Journal of Medicinal Chemistry

Volumn 54, Issue 24, 2011, Pages 8278-8288

  Brizzi, Antonella ^a   Cascio, Maria Grazia ^b   Frosini, Maria ^a   Ligresti, Alessia ^b   Aiello, Francesca ^c   Biotti, Irene ^a   Brizzi, Vittorio ^a   Pertwee, Roger Guy ^d   Corelli, Federico ^a   Di Marzo, Vincenzo ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF CALABRIA   (Italy)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIHYDROXYPROPAN 2 YL 11 (2 HEXYL 5 HYDROXYPHENOXY)UNDECANOATE; 1,3 DIHYDROXYPROPAN 2 YL 11 (3 HYDROXY 5 PENTYLPHENOXY)UNDECANOATE; 1,3 DIHYDROXYPROPAN 2 YL 11 (4 HEXYL 3 HYDROXYPHENOXY)UNDECANOATE; 1,3 DIHYDROXYPROPAN 2 YL 11 [3 HYDROXY 5 (2 METHYLOCTAN 2 YL)PHENOXY]UNDECANOATE; 1,3 DIHYDROXYPROPAN 2 YL 12 [3 HYDROXY 5 (2 METHYLOCTAN2 YL)PHENOXY]DODECANOATE; 1,3 DIHYDROXYPROPAN 2 YL 8 (2 HEXYL 5 HYDROXYPHENOXY)OCTANOATE; 1,3 DIHYDROXYPROPAN 2 YL 8 (3 HYDROXY 5 PENTYLPHENOXY)OCTANOATE; 1,3 DIHYDROXYPROPAN 2 YL 8 (4 HEXYL 3 HYDROXYPHENOXY)OCTANOATE; 1,3 DIHYDROXYPROPAN 2 YL 8 [3 HYDROXY 5 (2 METHYLOCTAN 2 YL)PHENOXY]OCTANOATE; 2 [10 (3 HYDROXY 5 PENTYLPHENOXY]DECYLOXY)PROPANE 1,3 DIOL; 2 [10 (4 HEXYL 3 HYDROXYPHENOXY)DECYLOXY]PROPANE 1,3 DIOL; 2 [10 [3 HYDROXY 5 (2 METHYLOCTAN 2 YL)PHENOXY]DECYLOXY]PROPANE 1,3 DIOL; 2 [12 (3 HYDROXY 5 PENTYLPHENOXY)DODECYLOXY]PROPANE 1,3 DIOL; 2 [12 [3 HYDROXY 5 (2 METHYLOCTAN 2 YL)PHENOXY]DODECYLOXY]PROPANE 1,3 DIOL; 2 [6 (3 HYDROXY 5 PENTYLPHENOXY)HEXYLOXY]PROPANE 1,3 DIOL; 2 [6 (4 HEXYL 3 HYDROXYPHENOXY)HEXYLOXY]PROPANE 1,3 DIOL; 2 [6 [3 HYDROXY 5 (2 METHYLOCTAN 2 YL)PHENOXY]HEXYLOXY]PROPANE 1,3 DIOL; 2 [8 (3 HYDROXY 5 PENTYLPHENOXY)OCTYLOXY]PROPANE 1,3 DIOL; 2 [8 [3 HYDROXY 5 (2 METHYLOCTAN 2 YL)PHENOXY]OCTYLOXY]PROPANE 1,3 DIOL; 2 ARACHIDONOYLGLYCEROL; 2 ARACHIDONYL GLYCEROL ETHER; ANANDAMIDE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; ESTERASE; GLYCEROL DERIVATIVE; NOLADIN ETHER; RESORCINOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRODHAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; MOUSE; NONHUMAN; RECEPTOR AFFINITY;

ANIMALS; ARACHIDONIC ACIDS; BRAIN; CHO CELLS; CRICETINAE; CRICETULUS; CYTOCHROME P-450 CYP3A; ESTERASES; ESTERS; ETHERS; GLYCERIDES; HEK293 CELLS; HUMANS; MICE; MOLECULAR MIMICRY; MONOGLYCERIDES; PHENOLS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RESORCINOLS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84055221870     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200529h     Document Type: Article

References (55)

1. Di Marzo, V.; Fontana, A. Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. Prostaglandins, Leukotrienes Essent. Fatty Acids 1995, 53, 1-11.
2. (a) Devane, W. A.; Dysarz, F. A.; Johnson, M. R.; Melvin, L. S.; Howlett, C. A. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 1988, 34, 605-613.
3. (b) Matsuda, L.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346, 561-564.
4. (c) Gerard, C. M.; Mollereau, C.; Vassaet, G.; Parmentier, M. Molecular Cloning of a Human Cannabinoid Receptor Which is also Expressed in Testis. Biochem. J. 1991, 279, 129-134.
5. (d) Herkenham, M. Localisation of cannabinoid receptors in brain and periphery. In Cannabinoid Receptors; Pertwee, R. G., Ed.; Academic Press: New York, 1995; pp 145-166.
6. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365, 61-65.
7. (a) Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258, 1946-1949.
8. (b) Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Almog, S.; Martin, B. R.; Compton, R. B.; Pertwee, R. G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z. Identification of an endogenous 2-monoglyceride, present in canine gut that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50, 83-90.
9. (c) Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoyl-glycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 1995, 215, 89-97.
10. (a) Di Marzo, V.; Petrosino, S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol. 2007, 18, 129-140.
11. (b) Liu, J.; Wang, L.; Harvey-White, J.; Huang, B. X.; Kim, H. Y.; Luquet, S.; Palmiter, R. D.; Krystal, G.; Rai, R.; Mahadevan, A.; Razdan, R. K.; Kunos, G. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 2008, 54, 1-7.
12. Blankman, J. L.; Simon, G. L.; Cravatt, B. F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 2007, 14, 1347-1356.
13. De Petrocellis, L.; Di Marzo, V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract. Res., Clin. Endocrinol. Metab. 2009, 23, 1-15.
14. 1 receptor. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3662-3665.
15. (b) Fezza, F.; Bisogno, T.; Minassi, A.; Appendino, G.; Mechoulam, R.; Di Marzo, V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 2002, 513, 294-298.
16. 1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 2000, 351, 817-824.
17. (b) Huang, S. M.; Bisogno, T.; Trevisani, M.; Al-Hayani, A.; De Petrocellis, L.; Fezza, F.; Tognetto, M.; Petros, T. J.; Krey, J. F.; Chu, C. J.; Miller, J. D.; Davies, S. N.; Geppetti, P.; Walker, J. M.; Di Marzo, V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 8400-8405.
18. 1 receptor. J. Pharmacol. Exp. Ther. 2002, 301, 1020-1024.
19. (b) Walker, J. M.; Krey, J. F.; Chu, C. J.; Huang, S. M. Endocannabinoids and related fatty acid derivatives in pain modulation. Chem. Phys. Lipids 2002, 121, 159-172.
20. 1 cannabinoid receptors. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 20588-20593.
21. Stella, N.; Schweitzer, P.; Piomelli, D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997, 388, 773-778.
22. (a) Gonsiorek, W.; Lunn, C.; Fan, X.; Narula, S.; Lundell, D.; Hipkin, R.W. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol. Pharmacol. 2000, 47, 1045-1050.
23. 1 receptor-dependent G-protein activation in rat cerebellar membranes. Br. J. Pharmacol. 2001, 134, 664-672.
24. 2 Receptor. Comparision of the Agonistic Activities of Various Cannabinoid Receptor Ligands in HL-60 Cells. J. Biol. Chem. 2000, 275, 605-612.
25. (b) Sugiura, T.; Kishimoto, S.; Oka, S.; Gokoh, M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog. Lipid Res. 2006, 45, 405-446.
26. (a) Dinh, T. P.; Carpenter, D.; Leslie, F. M.; Freund, T. F.; Katona, I.; Sensi, S. L.; Kathuria, S.; Piomelli, D. Brain mono-glyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 10819-10824.
27. (b) Dinh, T. P.; Kathuria, S.; Piomelli, D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol. Pharmacol. 2004, 66, 1260-1264.
28. Sugiura, T.; Kodaka, T.; Nakane, S.; Miyashita, T.; Kondo, S.; Suhara, Y.; Takayama, H.; Waku, K.; Seki, C.; Baba, N.; Ishima, Y. Evidence that the CB1 cannabinoid receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J. Biol. Chem. 1999, 274, 2794-2801.
29. Oka, S.; Tsuchie, A.; Tokumura, A.; Muramatsu, M.; Suhara, Y.; Takayama, H.; Waku, K.; Sugiura, T. Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J. Neurochem. 2003, 85, 1374-1381.
30. 1 receptor. Biochem. Pharmacol. 2005, 69, 169-178.
31. (a) Shoemaker, J. L.; Joseph, B. K.; Ruckle, M. B.; Mayeux, P. R.; Prather, P. L. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J. Pharmacol. Exp. Ther. 2005, 314, 868-875.
32. (b) Páldyová, E.; Bereczki, E.; Sántha, M.; Wenger, T.; Borsodi, A.; Benyhe, S. Noladin ether, a putative endocannabinoid, inhibits μ-opioid receptor activation via CB2 cannabinoid receptors. Neurochem. Int. 2008, 52, 321-328.
33. Laine, K.; Jarvinen, K.; Mechoulam, R.; Breuer, A.; Jarvinen, T. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest. Ophthalmol. Visual Sci. 2002, 43, 3216-3222.
34. (a) Suhara, Y.; Nakane, S.; Arai, S.; Takayama, H.; Waku, K.; Ishima, Y.; Sugiura, T. Synthesis and biological activities of novel structural analogues of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Bioorg. Med. Chem. Lett. 2001, 11, 1985-1988.
35. (b) Parkkari, T.; Salo, O. M. H.; Huttunen, K. M.; Savinainen, J. R.; Laitinen, J. T.; Poso, A.; Nevalainen, T.; Järvinen, T. Synthesis and CB1 receptor activities of dimethylheptyl derivatives of 2-arachidonoyl glycerol (2-AG) and 2-arachidonyl glyceryl ether (2-AGE). Biorg. Med. Chem. 2006, 14, 2850-2858.
36. 1 receptors. Bioorg. Med. Chem. Lett. 2003, 13, 43-46.
37. (b) Juntunen, J.; Vepsäläinen, J.; Niemi, R.; Laine, K.; Järvinen, T. Synthesis, in vitro evaluation, and intraocular pressure effects of water-soluble prodrugs of endocannabinoid noladin ether. J. Med. Chem. 2003, 46, 5083-5086.
38. (a) Brizzi, A.; Brizzi, V.; Cascio, M. G.; Bisogno, T.; Siriani, R.; Di Marzo, V. Design, Synthesis and Binding Studies of New Potent Ligands of Cannabinoid Receptors. J. Med. Chem. 2005, 48, 7343-7350.
39. (b) Brizzi, A.; Cascio, M. G.; Brizzi, V.; Bisogno, T.; Dinatolo, M. T.; Martinelli, A.; Tuccinardi, T.; Di Marzo, V. Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors. Bioorg. Med. Chem. 2007, 15, 5406-5416.
40. (c) Brizzi, A.; Brizzi, V.; Cascio, M. G.; Corelli, F.; Guida, F.; Ligresti, A.; Maione, S.; Martinelli, A.; Pasquini, S.; Tuccinardi, T.; Di Marzo, V. New Resorcinol-Anandamide "Hybrids" as Potent Cannabinoid Receptor Ligands Endowed with Antinociceptive Activity in Vivo. J. Med. Chem. 2009, 52, 2506-2514.
41. Mechoulam, R.; Fride, E.; Di Marzo, V. Endocannabinoids. Eur. J. Pharmacol. 1998, 359, 1-18.
42. Pertwee, R. G. Pharmacology of Cannabinoid receptor ligands. Curr. Med. Chem. 1999, 6, 635-664.
43. Gonzalez, F. J. The molecular biology of cytochrome P450s. Pharmacol. Rev. 1989, 40, 243-288.
44. Smith, D. A.; Jones, B. C.; Walker, D. K. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med. Res. Rev. 1996, 16, 243-266.
45. Di, L.; Kerns, E.; Li, S.; Carter, G. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. Int. J. Pharm. 2007, 335, 1-11.
46. Lewbart, M. L.; Schneider, J. J. Preparation and properties of steroidal 17,20- and 20,21-acetonides epimeric at C-20. I. Derivatives of 5b-Pregnan-3a-ol. J. Org. Chem. 1969, 34, 3505-3512.
47. Martin, J. B. The equilibrium between symmetrical and unsymmetrical monoglycerides and determination of total monoglycerides. J. Am. Chem. Soc. 1953, 75, 5483-5485.
48. Schmid, P. C.; Schwartz, K. D.; Smith, C. N.; Krebsbach, R. J.; Berdyshev, E. V.; Schmid, H. H. O. A sensitive endocannabinoid assay. The simultaneous analysis of N-acylethanolamines and 2-monoacylglycerols. Chem. Phys. Lipids 2000, 104, 185-191.
49. Saadea, M.; Magdaloub, J.; Ouainia, N; Greige-Gergese, H. Stability of cucurbitacin E in human plasma: chemical hydrolysis and role of plasma esterases. Biopharm. Drug Dispos. 2009, 30, 389-397.
50. Rouzer, C. A.; Ghebreselasie, K.; Marnett, L. J. Chemical stability of 2-arachidonylglycerol under biological conditions. Chem. Phys. Lipids 2002, 119, 69-82.
51. Di Marzo, V.; Griffin, G.; De Petrocellis, L.; Brandi, I.; Bisogno, T.; Williams, W.; Grier, M. C.; Kulasegram, S.; Mahadevan, A.; Razdan, R. K.; Martin, B. R. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J. Pharmacol. Exp. Ther. 2002, 300, 984-991.
52. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
53. (a) Breivogel, C. S.; Graeme, G.; Di Marzo, V.; Martin, B. R. Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain. Mol. Pharmacol. 2001, 60, 155-163.
54. (b) Kurkinen, K. M.; Koistinaho, J.; Laitinen, J. T. Gamma-35SGTP autoradiography allows region-specific detection of muscarinic receptor-dependent G-protein activation in the click optic tectum. Brain Res. 1997, 769, 21-28.
55. Ross, R. A.; Brockie, H. C.; Stevenson, L. A.; Murphy, V. L.; Templeton, F.; Makriyannis, A.; Pertwee, R. G. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L75956 and AM630. Br. J. Pharmacol. 1999, 126, 665-672.